pharma · EBV-induced Lymphomas · Coronary Artery Disease
Evidence Based Cataract
Evidence Based Cataract Study Group
Evidence Based Cataract clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- THOUSAND OAKS, CA, CN
- Programs
- 10
- Drugs
- 8
- Patents
- 10
Evidence Based Cataract projects
5 ClinicalTrials.gov programs sponsored by Evidence Based Cataract.
Evidence Based Cataract has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ATA188
Evidence Based Cataract Study Group
Primary Progressive Multiple Sclerosis
1 trial -
CMV-pp65 CTLs
Evidence Based Cataract Study Group
Cytomegalovirus
1 trial -
EBV-specific T cells (EBV-CTLs)
Evidence Based Cataract Study Group
EBV-induced Lymphomas
1 trial -
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Evidence Based Cataract Study Group
EBV-induced Lymphomas
1 trial -
Tabelecleucel
Evidence Based Cataract Study Group
Nasopharyngeal Carcinoma
1 trial
Frequently asked questions
How many clinical projects does Evidence Based Cataract have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.